Cancer Treatment and Research Communications (Jan 2022)

PRP-1, a toll-like receptor ligand, upregulates the unfolded protein response in human chondrosarcoma cells

  • Karina Galoian,
  • Victoria Dahl,
  • Andres Perez,
  • Carina Denny,
  • Beatrice Becker,
  • Anil Sedani,
  • Alexandra Moran,
  • Daniel Martinez,
  • Aaron Hoyt,
  • Jeffrey Brown

Journal volume & issue
Vol. 33
p. 100644

Abstract

Read online

Background: Previous studies showed that proline-rich polypeptide (PRP-1) is a ligand for innate immunity toll-like receptors (TLR), and an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) which induces the death of chondrosarcoma cancer stem cells (CSC). The aim of this study was to investigate the effect of PRP-1 on the regulation of unfolded protein response (UPR) in human chondrosarcoma cells. Materials and methods: Lysates were prepared from a monolayer (bulk or ALDHhigh population), or spheroids chondrosarcoma cell cultures and treated with PRP-1 or control, followed by protein levels quantification by western blotting and mRNA expression by RT-qPCR of protein-RNA-like endoplasmic reticulum kinase (PERK), eukaryotic translation initiation factor 2α (eIF2α), activating transcription factor 4 (ATF4), CCAAT-enhancer-binding protein homologous protein (CHOP), activating transcription factor 6 (ATF6), inositol-requiring enzyme 1 (IRE1α), and X-box binding protein (XBP1). Results: The PRP-1 has been shown to increase the expression of PERK, eIF2α, ATF4, CHOP, ATF6, IRE1α, and XBP1, on both protein and mRNA levels. Conclusion: PRP-1 activated UPR branches in monolayer, spheroid, and stem cell populations of human chondrosarcoma.

Keywords